Physician profile
Michael I Rotkowitz
NPI 1649436973
$19,534.85
in general payments reported to CMS, 2019-2025
42 companies · $3,568 in 2025
The $3,568 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $6,500 · 2021: $1,043 · 2022: $2,809 · 2023: $575 · 2024: $3,867 · 2025: $3,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,523 · Food and Beverage: $773 · Honoraria: $350 · Travel and Lodging: $299 · Education: $65.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,523.00 |
| Food and Beverage | $772.80 |
| Honoraria | $350.00 |
| Travel and Lodging | $298.62 |
| Education | $65.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,715.76 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Kite Pharma, INC. | $3,300.00 | 2020-2022 | |
| Karyopharm Therapeutics INC. | $2,325.00 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $1,725.00 | 2020 | |
| Genzyme Corporation | $1,115.00 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 | |
| Daiichi Sankyo INC. | $749.16 | 2019-2025 | Vanflyta, Enhertu |
| Glaxosmithkline, LLC. | $574.73 | 2022-2023 | Zejula |
| Regeneron Pharmaceuticals, INC. | $350.00 | 2025 | Lynozyfic |
| Dr.Reddy'S Laboratories,INC. | $333.00 | 2024 | |
| Sentynl Therapeutics, INC. | $309.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $300.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $252.66 | 2019-2023 | Opdivo |
| Incyte Corporation | $224.45 | 2020-2025 | Zynyz |
| Regeneron Healthcare Solutions, INC. | $147.68 | 2019-2024 | Libtayo |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rotkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.